glp-1 drugs pharmaceutical companies 2025 How Supply and Demand for Weight Loss is Playing Out in 2026 GLP-1 Receptor Agonist Market Size
Description
The results of a trial of semaglutide in obese patients with HFpEF showed a significant amelioration of symptoms and improvements in motor function and weight loss compared with patients treated with a placebo
doi: 10.1016/j.cbi.2018.01.004
Though several molecules, such as mazdutide, a GLP/glucagon dual agonist, are being studied in various phases, the first agent targeting incretins other than just GLP-1 was approved in 2022 tirzepatide [41]
The safety and tolerability of LY were monitored through vital signs, laboratory data, and adverse events (AEs)
